

Cover Story
Conversation with The Cancer LetterFree
A year after starting his job as NCI director, Ned Sharpless is reviewing the entire spectrum of NCI research in an effort to focus on areas where the institute plays a key role.
In Brief


Clinical Roundup
Drugs & Targets


Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members














